1. Home
  2. NAMSW vs MIR Comparison

NAMSW vs MIR Comparison

Compare NAMSW & MIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAMSW
  • MIR
  • Stock Information
  • Founded
  • NAMSW N/A
  • MIR 2005
  • Country
  • NAMSW Netherlands
  • MIR United States
  • Employees
  • NAMSW 29
  • MIR N/A
  • Industry
  • NAMSW Biotechnology: Pharmaceutical Preparations
  • MIR Industrial Machinery/Components
  • Sector
  • NAMSW Health Care
  • MIR Technology
  • Exchange
  • NAMSW Nasdaq
  • MIR Nasdaq
  • Market Cap
  • NAMSW N/A
  • MIR N/A
  • IPO Year
  • NAMSW N/A
  • MIR N/A
  • Fundamental
  • Price
  • NAMSW $8.90
  • MIR $10.61
  • Analyst Decision
  • NAMSW
  • MIR Strong Buy
  • Analyst Count
  • NAMSW 0
  • MIR 1
  • Target Price
  • NAMSW N/A
  • MIR $14.00
  • AVG Volume (30 Days)
  • NAMSW N/A
  • MIR 959.1K
  • Earning Date
  • NAMSW N/A
  • MIR 08-01-2024
  • Dividend Yield
  • NAMSW N/A
  • MIR N/A
  • EPS Growth
  • NAMSW N/A
  • MIR N/A
  • EPS
  • NAMSW N/A
  • MIR N/A
  • Revenue
  • NAMSW N/A
  • MIR $811,400,000.00
  • Revenue This Year
  • NAMSW N/A
  • MIR $7.48
  • Revenue Next Year
  • NAMSW N/A
  • MIR $5.65
  • P/E Ratio
  • NAMSW N/A
  • MIR N/A
  • Revenue Growth
  • NAMSW N/A
  • MIR 10.14
  • 52 Week Low
  • NAMSW N/A
  • MIR $6.70
  • 52 Week High
  • NAMSW N/A
  • MIR $11.78
  • Technical
  • Relative Strength Index (RSI)
  • NAMSW 46.37
  • MIR 46.39
  • Support Level
  • NAMSW $8.30
  • MIR $10.95
  • Resistance Level
  • NAMSW $9.77
  • MIR $11.13
  • Average True Range (ATR)
  • NAMSW 0.27
  • MIR 0.32
  • MACD
  • NAMSW -0.10
  • MIR -0.04
  • Stochastic Oscillator
  • NAMSW 28.57
  • MIR 4.47

About NAMSW NewAmsterdam Pharma Company N.V. Warrant

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Share on Social Networks: